- ICH GCP
- US-Register für klinische Studien
- Klinische Studie NCT00097227
Trial of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC)
A Randomized Phase II Trial of Two Dose Schedules of Carboplatin/Paclitaxel/Cetuximab in Stage IIIB/IV Non-small Cell Lung Cancer
Studienübersicht
Status
Bedingungen
Intervention / Behandlung
Detaillierte Beschreibung
Lung cancer is the second most common cancer diagnosed for both genders in the United States. Approximately 173,770 new cases are estimated for 2004. It is the leading cause of cancer deaths in both men and women, with approximately 160,440 deaths estimated for 2004. Prognosis for many is poor if not diagnosed at an early stage, and therapy for advanced disease is limited. The study will test two chemotherapy agents, carboplatin and paclitaxel, in combination with a newly approved drug called cetuximab, which is continuing to be tested in colorectal cancer and other cancers. Cetuximab is a monoclonal antibody, which is believed to work by attaching to an epidermal growth factor receptor (EGFR) on tumor cells and thereby blocking tumor cells from reproducing. It is an antibody to the EGFR. Fifty percent of lung cancers overexpress EGFR.
Rationale:
The present study is built upon the data from previous studies, incorporating cetuximab into each of two regimens of paclitaxel plus carboplatin. The results of prior studies using paclitaxel and carboplatin demonstrate that these drugs in combination, using a variety of schedules, are both safe and effective as therapy for advanced or metastatic NSCLC. The addition of biologic therapy with the anti-EGFR agent cetuximab to the combination will presumably maximize the therapeutic index while keeping toxicity to a minimum in patients with Stage IIIB/IV NSCLC.
Research Hypothesis:
Subjects with previously-untreated stage IIIB/IV NSCLC who receive a combination of paclitaxel, carboplatin, and cetuximab will have a progression-free survival rate greater than that previously reported for subjects receiving the combination of paclitaxel and carboplatin.
Studientyp
Einschreibung (Tatsächlich)
Phase
- Phase 2
Kontakte und Standorte
Studienorte
-
-
California
-
Los Angeles, California, Vereinigte Staaten, 90089
- ImClone Investigational Site
-
Santa Monica, California, Vereinigte Staaten, 90404
- ImClone Investigational Site
-
-
Delaware
-
Newark, Delaware, Vereinigte Staaten, 19713
- ImClone Investigational Site
-
-
Florida
-
Orlando, Florida, Vereinigte Staaten, 32804
- ImClone Investigational Site
-
St. Petersburg, Florida, Vereinigte Staaten, 33705
- ImClone Investigational Site
-
-
Georgia
-
Tucker, Georgia, Vereinigte Staaten, 30084
- ImClone Investigational Site
-
-
Indiana
-
Terra Haute, Indiana, Vereinigte Staaten, 47804
- ImClone Investigational Site
-
-
Kentucky
-
Louisville, Kentucky, Vereinigte Staaten, 40202
- ImClone Investigational Site
-
-
Maryland
-
Baltimore, Maryland, Vereinigte Staaten, 21204
- ImClone Investigational Site
-
-
Michigan
-
Ypsilanti, Michigan, Vereinigte Staaten, 48197
- ImClone Investigational Site
-
-
New Jersey
-
Newark, New Jersey, Vereinigte Staaten, 07112
- ImClone Investigational Site
-
-
North Carolina
-
Chapel Hill, North Carolina, Vereinigte Staaten, 27599
- ImClone Investigational Site
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Vereinigte Staaten, 19141
- ImClone Investigational Site
-
-
South Carolina
-
Columbia, South Carolina, Vereinigte Staaten, 29209
- ImClone Investigational Site
-
-
Tennessee
-
Knoxville, Tennessee, Vereinigte Staaten, 37920
- ImClone Investigational Site
-
-
Texas
-
Houston, Texas, Vereinigte Staaten, 77024
- ImClone Investigational Site
-
Temple, Texas, Vereinigte Staaten, 76508
- ImClone Investigational Site
-
-
Virginia
-
Richmond, Virginia, Vereinigte Staaten, 23230
- ImClone Investigational Site
-
-
Washington
-
Tacoma, Washington, Vereinigte Staaten, 98405
- ImClone Investigational Site
-
-
West Virginia
-
Morgantown, West Virginia, Vereinigte Staaten, 26506
- ImClone Investigational Site
-
-
Teilnahmekriterien
Zulassungskriterien
Studienberechtigtes Alter
Akzeptiert gesunde Freiwillige
Studienberechtigte Geschlechter
Beschreibung
Inclusion Criteria:
To be eligible for the study, subjects must fulfill all of the following criteria and have a complete signed informed consent form.
- Subjects must have signed an approved informed consent.
- Subjects with histologically or cytologically documented stage IIIB (supraclavicular lymph node, high neck node, or pleural effusion involvement) or IV NSCLC. Disease must be newly diagnosed or recurrent at least 1 year post adjuvant therapy.
- Subjects with measurable disease.
- Subjects with ECOG performance status 0-1.
- Subjects with asymptomatic brain metastasis are eligible; however, they must have completed radiotherapy/radiosurgery at least 2 weeks prior to enrollment and be off steroids.
- Radiotherapy must have been completed > 2 weeks prior to enrollment and the subject must have recovered from all adverse effects of prior radiotherapy. No previous irradiation to the only area of measurable disease. New lesions that developed in a previously irradiated area will be allowed.
- If diagnostic tissue or slides are available for a subject, these must be submitted for testing of EGFR status.
- Subjects ≥18 years of age.
- Women of childbearing potential (WOCBP) must be using an adequate method of contraception to avoid pregnancy throughout the study and for up to 4 weeks after the study in such a manner that the risk of pregnancy is minimized. WOCBP include any female who has experienced menarche and who has not undergone successful surgical sterilization (hysterectomy, bilateral tubal ligation or bilateral oophorectomy) or is not postmenopausal [defined as amenorrhea ≥12 consecutive months; or women on hormone replacement therapy (HRT) with documented serum follicle stimulating hormone (FSH) level >35mIU/mL]. Even women who are using oral, implanted or injectable contraceptive hormones or mechanical products such as an intrauterine device or barrier methods (diaphragm, condoms, spermicides) to prevent pregnancy or practicing abstinence or where partner is sterile (e.g., vasectomy), should be considered to be of child bearing potential. WOCBP must have a negative serum or urine pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 72 hours prior to the start of study medication.
Subjects with adequate hematologic function defined as: ANC ≥1,500/mm 3 ; WBC
≥3,000/mm 3 ; platelets ≥100,000/mm 3 ; and hemoglobin ≥9 g/dL.
- Subjects with adequate hepatic function defined as: total bilirubin ≤1.5 x upper limit of normal (ULN) or AST ≤2.5 x ULN.
- Subjects with adequate renal function defined as a serum creatinine level ≤1.5 mg/dL or a creatinine clearance ≥60 cc/minute.
Exclusion Criteria:
Any of the following criteria will make the subject ineligible to participate in this study.
- WOCBP who are unwilling or unable to use an acceptable method to avoid pregnancy for the entire study period and for up to 4 weeks after the study. Subjects who are men must also agree to use effective contraception.
- WOCBP using a prohibited contraceptive method.
- Women who are pregnant or breastfeeding.
- Women with a positive pregnancy test on enrollment or prior to study drug administration.
- Subjects who have had prior malignancy, except for adequately treated basal cell or squamous cell skin cancer, in situ cervical cancer, or other cancer for which the subject has been disease-free for 5 years.
- Subjects with significant history of cardiac disease, i.e., uncontrolled hypertension, unstable angina, uncontrolled congestive heart failure, cardiomyopathy with decreased ejection fraction, myocardial infarction within the past year, or cardiac ventricular arrythmias requiring medication.
- Subjects with an uncontrolled seizure disorder, or active neurological disease.
- Subjects with symptomatic brain metastasis. Prohibited Therapies and/or Medications
- Subjects who have received prior systemic chemotherapy. Subjects with no more than one prior adjuvant regimen for initially diagnosed disease are eligible for the study.
- Subjects with a history of prior cetuximab or other therapy that specifically and directly targets the EGFR pathway.
- Subject with prior severe infusion reaction to a monoclonal antibody.
- Subjects with know allergy to Cremophor EL.
- Subjects with known peripheral neuropathy (> grade 1).
- Subjects with prior erythropoietin (i.e., Epogen, Procrit) treatment.
- Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) for treatment of either a psychiatric or physical (e.g., infectious disease) illness.
Studienplan
Wie ist die Studie aufgebaut?
Designdetails
- Hauptzweck: Behandlung
- Zuteilung: Zufällig
- Interventionsmodell: Parallele Zuordnung
- Maskierung: Keine (Offenes Etikett)
Waffen und Interventionen
Teilnehmergruppe / Arm |
Intervention / Behandlung |
---|---|
Aktiver Komparator: Arm A (3-week cycle)
Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion. Paclitaxel 225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks. Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks. |
(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion. A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B.
Andere Namen:
(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
Andere Namen:
225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.
OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
Andere Namen:
|
Aktiver Komparator: Arm B (4-week cycle)
Cetuximab was administered weekly at an initial dose (Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion. Paclitaxel 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle. Carboplatin (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks. |
(Week 1) of 400 mg/m2 IV infusion and a weekly maintenance dose of 250 mg/m2 IV infusion. A cycle of therapy was defined as 3 weeks in Arm A and 4 weeks in Arm B.
Andere Namen:
(AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 3 weeks (AUC = 6) was infused over 30 minutes on Day 1 and subsequently every 4 weeks.
Andere Namen:
225 mg/m2 infused over 180 minutes on Day 1 and subsequently every 3 weeks.
OR 100 mg/m2 infused over 180 minutes on Day 1, Day 8 and Day 15 of a 4-week cycle.
Andere Namen:
|
Was misst die Studie?
Primäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
To estimate median progression free survival and the progression free survival rate
Zeitfenster: 6 months
|
6 months
|
Sekundäre Ergebnismessungen
Ergebnis Maßnahme |
Zeitfenster |
---|---|
To estimate the overall response rate in each treatment arm
Zeitfenster: 6 months
|
6 months
|
To estimate median survival and the survival rate at one year in each treatment arm
Zeitfenster: 6 months
|
6 months
|
To evaluate the toxicity profile of each treatment arm
Zeitfenster: 6 months
|
6 months
|
To explore the relationship between EGFR expression and the "clinical benefit" received from each treatment regimen
Zeitfenster: 6 months
|
6 months
|
To evaluate symptom response rate in each treatment arm using the Lung Cancer Subscale (LCS) of the FACT-L
Zeitfenster: 6 months
|
6 months
|
Mitarbeiter und Ermittler
Sponsor
Mitarbeiter
Studienaufzeichnungsdaten
Haupttermine studieren
Studienbeginn
Primärer Abschluss (Tatsächlich)
Studienabschluss (Tatsächlich)
Studienanmeldedaten
Zuerst eingereicht
Zuerst eingereicht, das die QC-Kriterien erfüllt hat
Zuerst gepostet (Schätzen)
Studienaufzeichnungsaktualisierungen
Letztes Update gepostet (Schätzen)
Letztes eingereichtes Update, das die QC-Kriterien erfüllt
Zuletzt verifiziert
Mehr Informationen
Begriffe im Zusammenhang mit dieser Studie
Schlüsselwörter
Zusätzliche relevante MeSH-Bedingungen
- Erkrankungen der Atemwege
- Neubildungen
- Lungenkrankheit
- Neubildungen nach Standort
- Neubildungen der Atemwege
- Thoraxneoplasmen
- Karzinom, bronchogen
- Bronchiale Neubildungen
- Lungentumoren
- Karzinom, nicht-kleinzellige Lunge
- Molekulare Mechanismen der pharmakologischen Wirkung
- Antineoplastische Mittel
- Tubulin-Modulatoren
- Antimitotische Mittel
- Mitose-Modulatoren
- Antineoplastische Mittel, Phytogen
- Antineoplastische Mittel, immunologische
- Carboplatin
- Paclitaxel
- Cetuximab
Andere Studien-ID-Nummern
- CA225-058
Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .
Klinische Studien zur Nicht-kleinzelligem Lungenkrebs
-
National Cancer Institute (NCI)AbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes diffuses gemischtzelliges Lymphom | AIDS-bedingtes kleines Noncleaved-Cell-LymphomVereinigte Staaten
-
National Cancer Institute (NCI)AbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes immunoblastisches großzelliges Lymphom | AIDS-bedingtes kleines Noncleaved-Cell-LymphomVereinigte Staaten
-
Jason Robert GotlibNovartis; Novartis PharmaceuticalsAbgeschlossenSystemische Mastozytose, aggressiv (ASM) | Leukämie, Mastzelle | Hämatologische Non-Mast Cell Lineage Disease (AHNMD)Vereinigte Staaten
-
Adelphi Values LLCBlueprint Medicines CorporationAbgeschlossenMastzellleukämie (MCL) | Aggressive systemische Mastozytose (ASM) | SM w Assoc Clonal Hema Non-Mast Cell Lineage Disease (SM-AHNMD) | Schwelende systemische Mastozytose (SSM) | Indolente systemische Mastozytose (ISM) ISM-Untergruppe vollständig rekrutiertVereinigte Staaten
-
Children's Oncology GroupNational Cancer Institute (NCI)AbgeschlossenDiffuses großzelliges Lymphom im Kindesalter | Immunoblastisches großzelliges Lymphom im Kindesalter | Burkitt-Lymphom im Kindesalter | Unbehandelte akute lymphoblastische Leukämie im Kindesalter | Stadium I des großzelligen Lymphoms im Kindesalter | Stadium I des kleinen, nicht gespaltenen... und andere BedingungenVereinigte Staaten
-
SWOG Cancer Research NetworkNational Cancer Institute (NCI); Genentech, Inc.RekrutierungDiffuses großzelliges B-Zell-Lymphom | Wiederkehrendes diffuses großzelliges B-Zell-Lymphom | Refraktäres diffuses großzelliges B-Zell-Lymphom | Primäres mediastinales (thymisches) großes B-Zell-Lymphom | Follikuläres Lymphom Grad 3b | Transformierte follikuläre Lymphe zu Diff Large B-Zell-Lymphom und andere BedingungenVereinigte Staaten
-
Mitchell CairoRekrutierungHodgkin-Lymphom | Sichelzellenanämie | Akute Leukämie | Beta-Thalassämie | Non-Hodgkin-Lymphom | Schwere aplastische Anämie | Diamond-Blackfan-Anämie | Amegakaryozytäre Thrombozytopenie | KostmannVereinigte Staaten
-
National Cancer Institute (NCI)BeendetLymphoproliferative Störung nach der Transplantation | Rezidivierendes großzelliges Lymphom im Kindesalter | Rezidivierendes kindliches lymphoblastisches Lymphom | Rezidivierendes kleinzelliges Lymphom im Kindesalter | Rezidivierendes/refraktäres Hodgkin-Lymphom im Kindesalter | AIDS-bedingtes... und andere BedingungenVereinigte Staaten
-
National Cancer Institute (NCI)Aktiv, nicht rekrutierendWeichteilsarkom | Osteosarkom | Ewing-Sarkom | Bösartiges Gliom | Ependymom | Rhabdoider Tumor | Fortgeschrittenes bösartiges solides Neoplasma | Refraktärer bösartiger fester Neoplasma | Rhabdomyosarkom | Rezidivierende bösartige solide Neubildung | Rezidivierendes Neuroblastom | Refraktäres Neuroblastom | Refraktäres... und andere BedingungenVereinigte Staaten, Puerto Rico
-
AIDS Malignancy ConsortiumNational Cancer Institute (NCI); University of Arkansas; The Emmes Company, LLCAbgeschlossenAIDS-bedingtes peripheres/systemisches Lymphom | AIDS-assoziiertes diffuses großzelliges Lymphom | AIDS-bedingtes diffuses gemischtzelliges Lymphom | AIDS-bedingtes diffuses kleinzelliges Lymphom | AIDS-bedingtes immunoblastisches großzelliges Lymphom | AIDS-assoziiertes lymphoblastisches... und andere BedingungenZimbabwe, Kenia
Klinische Studien zur Cetuximab
-
University Medical Center GroningenUMC Utrecht; Erasmus Medical CenterRekrutierungKopf-Hals-Plattenepithelkarzinom | MargenbewertungNiederlande
-
West China HospitalFirst Affiliated Hospital of Chongqing Medical UniversityRekrutierungDickdarmkrebs | Capecitabin | CetuximabChina
-
Amsterdam UMC, location VUmcRadboud University Medical Center; University Medical Center GroningenBeendetMetastasierter DarmkrebsNiederlande
-
Eben RosenthalNational Cancer Institute (NCI)BeendetAdenokarzinom des PankreasVereinigte Staaten
-
HiberCell, Inc.BeendetDarmkrebsVereinigte Staaten, Puerto Rico, Deutschland, Frankreich
-
Merck KGaA, Darmstadt, GermanyAbgeschlossenZuvor unbehandelter metastasierter DarmkrebsFrankreich, Italien, Polen, Deutschland, Hongkong, Österreich, Brasilien, Israel, Griechenland, Argentinien, Thailand, Belgien, Australien, Mexiko
-
Merck KGaA, Darmstadt, GermanyAbgeschlossenNicht-kleinzelliger Lungenkrebs (NSCLC)Deutschland
-
Arbeitsgemeinschaft medikamentoese TumortherapieMerck Sharp & Dohme LLCAbgeschlossen
-
Universitaire Ziekenhuizen KU LeuvenMerck KGaA, Darmstadt, GermanyAbgeschlossenDarmkrebsSpanien, Frankreich, Belgien, Ungarn, Österreich
-
Cancer Institute and Hospital, Chinese Academy...Rekrutierung